Responder rates at Week 52 in QUEST (secondary endpoint)1,2,a,b

Improved asthma control in patients, as measured by ACQ-5
Baseline Blood
EOS ≥300 cells/μL - QUEST
75%
of patients improved

with DUPIXENT 200 mg + SOC
vs 67% with placebo + SOC
(OR: 1.46 [95% CI: 0.90, 2.35])

71%
of patients improved

with DUPIXENT 300 mg + SOC vs 64% with placebo + SOC (OR: 1.39 [95% CI: 0.88, 2.19])

ACQ-5: Asthma Control Questionnaire, 5-item version, a patient-reported measure of asthma control. Higher scores indicate less asthma control; a global score is calculated ranging from 0 to 6. The minimum clinically important difference is 0.5.1

 

Improved asthma in patients’ quality of life, as measured by AQLQ(S)
Baseline Blood
EOS ≥300 cells/μL - QUEST
71%
of patients improved

with DUPIXENT 200 mg + SOC
vs 55% with placebo + SOC
(OR: 2.02 [95% CI: 1.24, 3.32])

65%
of patients improved

with DUPIXENT 300 mg + SOC
vs 55% with placebo + SOC
(OR: 1.79 [95% CI: 1.13, 2.85])

AQLQ(S): Asthma Quality of Life Questionnaire, Standardized Version, a patient-reported measure of asthma-related quality of life. Higher scores indicate better quality of life; a global score is calculated ranging from 1 to 7. The minimum clinically important difference is 0.5.1

aResponder rates were defined as an improvement in score of 0.5 or more (scale ranged from 0 to 6 for ACQ-5 and 1 to 7 for AQLQ[S]).1

bACQ-5 and AQLQ(S) were assessed as secondary endpoints, but were ordered after the point at which the hierarchical break occurred. Results are descriptive.2

QoL, quality of life.